ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Recommendation of "Moderate Buy" by Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $12.50.

Several equities analysts recently issued reports on ALXO shares. UBS Group decreased their target price on ALX Oncology from $25.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday, August 16th. Lifesci Capital lowered shares of ALX Oncology from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 31st. HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of ALX Oncology in a research note on Tuesday, August 13th. Cantor Fitzgerald reissued an "overweight" rating on shares of ALX Oncology in a research report on Tuesday, November 12th. Finally, Stifel Nicolaus restated a "hold" rating and set a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th.

ALX Oncology Trading Up 1.3 %

NASDAQ ALXO traded up $0.02 on Thursday, reaching $1.51. The stock had a trading volume of 330,462 shares, compared to its average volume of 780,531. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The stock has a fifty day moving average price of $1.56 and a two-hundred day moving average price of $4.64. ALX Oncology has a 12-month low of $1.19 and a 12-month high of $17.83. The firm has a market capitalization of $79.64 million, a price-to-earnings ratio of -0.51 and a beta of 1.03.

Institutional Investors Weigh In On ALX Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co purchased a new stake in shares of ALX Oncology in the 1st quarter valued at about $27,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ALX Oncology by 394.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company's stock worth $39,000 after purchasing an additional 5,200 shares in the last quarter. SG Americas Securities LLC grew its position in ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company's stock worth $50,000 after buying an additional 6,888 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology in the 2nd quarter worth approximately $63,000. Finally, GSA Capital Partners LLP acquired a new stake in ALX Oncology in the third quarter valued at $88,000. Institutional investors and hedge funds own 97.97% of the company's stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.